TapewireFind a company

person · Reporting owner

SMITH J. JEFFERSON

Disclosed activity across 1 company

Tapewire entity
41658
SEC CIK
0001770169

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PRECISION BIOSCIENCES INCDTIL · Entity 6284Chief Research OfficerJune 01, 2026June 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PRECISION BIOSCIENCES INC

Report date June 01, 2026 · Filed June 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect57,389 Reported balance After 2026-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-01 · Grant · Acquired 57,389 · Balance 57,389

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 01, 2026 Filed Jun 3, 2026 20:06 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 57,389 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-040223 · wk-form4_1780517196.xml · derivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,389

Underlying: Common Stock · 57,389 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 18, 2026 Filed Feb 19, 2026 21:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 4,925 $3.84 $18,912.00
Disclosure

SEC source: 0001628280-26-009801 · wk-form4_1771536640.xml · nonDerivative · entry 2

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,926

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 16,667 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-009801 · wk-form4_1771536640.xml · derivative · entry 4

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,333

Underlying: Common Stock · 16,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 16,667 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-009801 · wk-form4_1771536640.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 21, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 10,200 $4.03 $41,106.00
Disclosure

SEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · nonDerivative · entry 4

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,184

F4 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
January 21, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 16,219 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · nonDerivative · entry 3

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,384

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 16,219 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · derivative · entry 8

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,219

Underlying: Common Stock · 16,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F7 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F7 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 10,447 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · derivative · entry 7

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,447

Underlying: Common Stock · 10,447 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F6 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 2,500 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · derivative · entry 6

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F5 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 10,447 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · nonDerivative · entry 2

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 2,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · balance_after: Includes 3,413 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price per share of $5.74

Read SEC document
June 02, 2025 Filed Jun 4, 2025 21:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 50,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-081723 · ownership.xml · derivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 00:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 154 $4.91 $756.14
Disclosure

SEC source: 0000950170-25-034010 · ownership.xml · nonDerivative · entry 2

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,805

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
March 03, 2025 Filed Mar 6, 2025 00:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 519 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034010 · ownership.xml · derivative · entry 4

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 519 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 3, 2025.

F4 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 3, 2025.

Read SEC document
March 03, 2025 Filed Mar 6, 2025 00:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 519 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034010 · ownership.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,959

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on March 3, 2025.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 22, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 10,287 $4.79 $49,274.73
Disclosure

SEC source: 0000950170-25-008011 · ownership.xml · nonDerivative · entry 2

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,440

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 16,219 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-008011 · ownership.xml · derivative · entry 6

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,438

Underlying: Common Stock · 16,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F6 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 10,449 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-008011 · ownership.xml · derivative · entry 5

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,894

Underlying: Common Stock · 10,449 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F5 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 2,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-008011 · ownership.xml · derivative · entry 4

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 29,168 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-008011 · ownership.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2025.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
August 22, 2024 Filed Aug 23, 2024 11:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 48,657 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-100021 · ownership.xml · derivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,657

Underlying: Common Stock · 48,657 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
June 10, 2024 Filed Jun 11, 2024 21:12 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 50 $11.79 $589.50
Disclosure

SEC source: 0000950170-24-072049 · ownership.xml · nonDerivative · entry 2

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,559

F3 · kind: The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.70 to $12.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Read SEC document
June 07, 2024 Filed Jun 11, 2024 21:12 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 163 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-072049 · ownership.xml · derivative · entry 4

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 163 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on June 7, 2024.

F5 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on June 7, 2024.

Read SEC document
June 07, 2024 Filed Jun 11, 2024 21:12 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 163 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-072049 · ownership.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,609

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2024.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
May 08, 2024 Filed May 9, 2024 00:25 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 833 $12.00 $9,996.00
Disclosure

SEC source: 0000950170-24-056139 · ownership.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,446

F1 · shares: Represents shares purchased through a definitive subscription agreement, pursuant to which the Issuer agreed to issue and sell shares of its common stock in a non-brokered private placement to certain members of its management.

Read SEC document
May 02, 2024 Filed May 3, 2024 22:32 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 154 $10.32 $1,589.28
Disclosure

SEC source: 0000950170-24-053114 · ownership.xml · nonDerivative · entry 3

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,613

F4 · kind: The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.53. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:32 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 519 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-053114 · ownership.xml · derivative · entry 5

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 519

Underlying: Common Stock · 519 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F6 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:32 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 519 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-053114 · ownership.xml · nonDerivative · entry 2

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,767

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting of Restricted Stock Units ("RSUs") on March 3, 2024, and subsequent settlement of such vested RSUs on May 1, 2024.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · balance_after: On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split.

Read SEC document
April 18, 2024 Filed Apr 23, 2024 01:12 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 31,343 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-046599 · ownership.xml · derivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,343

Underlying: Common Stock · 31,343 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 29, 2024 Filed May 3, 2024 22:32 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 1,006 $12.42 $12,494.52
Disclosure

SEC source: 0000950170-24-053114 · ownership.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,248

Read SEC document
January 23, 2024 Filed Jan 24, 2024 00:11 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 28,000 $0.37 $10,360.00
Disclosure

SEC source: 0001209191-24-002113 · doc4.xml · nonDerivative · entry 2

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,987,269

F3 · kind: The transaction was a sell-to-cover, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The reporting person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35495 to $0.37790. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Read SEC document
January 20, 2024 Filed Jan 24, 2024 00:11 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 75,015 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-002113 · doc4.xml · derivative · entry 4

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,985

Underlying: Common Stock · 75,015 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

F5 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F5 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2024 Filed Jan 24, 2024 00:11 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 75,015 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-24-002113 · doc4.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,015,269

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2024.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

Read SEC document
August 31, 2023 Filed Sep 5, 2023 20:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 5,175 $0.39 $2,018.25
Disclosure

SEC source: 0001209191-23-048145 · doc4.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,940,254

F1 · kind: These shares were acquired under the Issuer's 2019 Employee Stock Purchase Plan subsequent to the Reporting Person's Form 4 filed on June 9, 2023.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 4,872 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-035790 · doc4.xml · derivative · entry 3

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,872

Underlying: Common Stock · 4,872 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

F3 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F3 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 4,872 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-035790 · doc4.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,935,079

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 22:12 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 15,576 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016842 · doc4.xml · derivative · entry 4

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,144

Underlying: Common Stock · 15,576 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F3 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 22:12 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 15,576 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016842 · doc4.xml · nonDerivative · entry 2

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,930,207

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on March 3, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
February 28, 2023 Filed Mar 7, 2023 22:12 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 12,157 $0.95 $11,549.15
Disclosure

SEC source: 0001209191-23-016842 · doc4.xml · nonDerivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,914,631

Read SEC document
January 20, 2023 Filed Jan 24, 2023 21:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 225,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-004611 · doc4.xml · derivative · entry 1

SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.